Suppliers and packagers for generic pharmaceutical drug: GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	gramicidin; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	064047	ANDA	Bausch & Lomb Incorporated	24208-790-62	1 BOTTLE, DROPPER in 1 CARTON (24208-790-62) / 10 mL in 1 BOTTLE, DROPPER	1996-01-31
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	gramicidin; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	064047	ANDA	A-S Medication Solutions	50090-0247-0	1 BOTTLE, DROPPER in 1 CARTON (50090-0247-0) / 10 mL in 1 BOTTLE, DROPPER	1996-01-31

Antibiotic Combination Drug Supply Chain Analysis: Gramicidin, Neomycin Sulfate, Polymyxin B Sulfate

Last updated: February 19, 2026

This analysis examines the global supply chain for key active pharmaceutical ingredients (APIs) – Gramicidin, Neomycin Sulfate, and Polymyxin B Sulfate – used in combination antibiotic formulations. It identifies primary manufacturers, their geographic distribution, and potential supply chain vulnerabilities.

Who are the Primary Manufacturers of Gramicidin?

Gramicidin is a mixture of linear and cyclic peptides produced by Bacillus brevis. The production process is fermentation-based, leading to a limited number of specialized manufacturers.

• Key Manufacturers:

  • Sigma-Aldrich (Merck KGaA): A major supplier of laboratory-grade and bulk pharmaceutical ingredients.
  • Thermo Fisher Scientific: Offers Gramicidin in various purities for research and manufacturing.
  • Bachem AG: A custom synthesis and peptide manufacturer that may produce Gramicidin on a contract basis.
  • Janssen Vaccines & Prevention (Johnson & Johnson): Historically involved in Gramicidin production for specific applications.

• Geographic Concentration: While distribution is global, primary manufacturing often originates in North America and Europe, leveraging established fermentation and purification expertise. Asia, particularly China and India, also has API manufacturers capable of producing Gramicidin, though market presence can vary.

• Production Capacity: Specific production volumes are proprietary. However, demand is generally stable, driven by established ophthalmic and topical antimicrobial formulations. Supply disruptions can arise from raw material availability for fermentation or specialized purification equipment downtime.

What are the Sources for Neomycin Sulfate?

Neomycin Sulfate is an aminoglycoside antibiotic produced by Streptomyces fradiae. Its manufacturing involves large-scale fermentation and subsequent complex purification steps.

• Key Manufacturers:

  • Pfizer Inc.: A significant producer of Neomycin Sulfate, supplying it for various pharmaceutical applications.
  • Sanofi S.A.: Historically a producer, with manufacturing capabilities for aminoglycoside antibiotics.
  • CSL Limited (formerly CSL Behring): Has a history in fermentation-derived products, potentially including Neomycin Sulfate.
  • Anhui Fengyuan Pharmaceutical Co., Ltd. (China): A major API producer in China with significant fermentation capacity.
  • Divi’s Laboratories Limited (India): A prominent Indian API manufacturer with a broad portfolio, including antibiotics.

• Geographic Distribution: Production is more diversified than Gramicidin, with substantial manufacturing bases in China and India. North America and Europe also maintain production capabilities, often for higher-purity or specialized grades.

• Supply Chain Dynamics: The market is influenced by large-scale fermentation operations. Price fluctuations can occur due to the cost of raw agricultural inputs for fermentation media and energy costs. Competition among Asian manufacturers is a significant factor in pricing and availability. Environmental regulations in manufacturing regions can also impact production costs and lead times.

Where is Polymyxin B Sulfate Manufactured?

Polymyxin B Sulfate is a polypeptide antibiotic produced by Bacillus polymyxa. Similar to Gramicidin, it is derived from fermentation, but its purification is particularly challenging due to its complex molecular structure.

• Key Manufacturers:

  • Xellia Pharmaceuticals ApS (Denmark): A leading global manufacturer specializing in fermentation-derived APIs, including Polymyxin B Sulfate.
  • Qilu Pharmaceutical Group (China): A large Chinese pharmaceutical company with significant API manufacturing capabilities.
  • Gruppo Chiesi (Italy): Known for its respiratory products, Chiesi has capabilities in fermentation and antibiotic production.
  • Sandoz (Novartis AG): As a major generic manufacturer, Sandoz has the capacity to produce or source Polymyxin B Sulfate.

• Geographic Concentration: Production is concentrated in regions with established expertise in complex fermentation and peptide purification. Europe and China are primary manufacturing hubs. The United States has limited bulk manufacturing but significant formulation capabilities.

• Production Challenges: The production of Polymyxin B is subject to batch variability. High purity standards are critical due to its parenteral and ophthalmic applications. Supply can be constrained by the availability of specialized fermentation equipment and skilled personnel for purification. The emergence of antibiotic resistance has led to renewed interest and potential increased demand, which could strain existing capacity.

What are the Potential Supply Chain Risks for these Antibiotics?

The supply chain for these three APIs faces several interconnected risks that could impact the availability and cost of combination antibiotic products.

• Raw Material Sourcing:

  • Fermentation Media: Fluctuations in the price and availability of agricultural products (e.g., glucose, soybean meal, yeast extract) used in fermentation media can affect production costs for Neomycin Sulfate and, to a lesser extent, Gramicidin and Polymyxin B.
  • Precursors and Solvents: The availability and purity of chemical precursors and solvents used in purification processes are critical. Geopolitical instability or trade restrictions impacting key chemical suppliers can create bottlenecks.

• Manufacturing and Quality Control:

  • Batch Variability: Fermentation processes are inherently variable. Maintaining consistent quality and yield requires stringent process controls and skilled labor. Deviations can lead to batch rejections and production delays.
  • Regulatory Compliance: API manufacturers must adhere to strict Good Manufacturing Practice (GMP) standards. Unexpected regulatory inspections, facility upgrades, or changes in regulatory requirements (e.g., ICH guidelines) can halt production or require significant capital investment.
  • Specialized Equipment: The purification of peptides like Gramicidin and Polymyxin B requires specialized chromatography equipment and filtration systems. Downtime for maintenance or failure of this equipment can have a disproportionate impact on output.

• Geopolitical and Economic Factors:

  • Trade Tensions and Tariffs: Import/export duties, trade disputes, and geopolitical tensions between major manufacturing nations (e.g., US-China) can disrupt global supply chains, increasing costs and lead times.
  • Currency Fluctuations: Significant shifts in exchange rates can impact the cost-competitiveness of API manufacturing in different regions.
  • Political Instability: Unrest or conflict in key manufacturing countries can lead to temporary or prolonged supply interruptions.

• Environmental Regulations:

  • Wastewater Treatment: Fermentation and chemical purification processes generate wastewater. Increasingly stringent environmental regulations, particularly in China and India, can necessitate substantial investment in treatment facilities, potentially impacting production capacity and cost.
  • Emissions Control: Air quality regulations can affect the operation of manufacturing plants.

• Logistics and Transportation:

  • Global Shipping Disruptions: Port congestion, container shortages, and increased shipping costs (as seen in recent years) can delay raw material inbound and API outbound shipments.
  • Cold Chain Requirements: While less common for these specific APIs in their bulk form, some intermediates or finished products might require specific temperature controls during transport, adding complexity and cost.

• Antimicrobial Resistance and Demand Shifts:

  • Increased Demand: The rising threat of antimicrobial resistance can lead to increased demand for older antibiotics like Neomycin and Polymyxin B, potentially straining existing production capacity if not managed proactively.
  • Withdrawal of Products: If a major combination product using these APIs is withdrawn from the market due to safety or efficacy concerns, it could reduce overall demand and impact the economic viability for certain manufacturers.

Comparative Analysis of API Supply Chains

Feature	Gramicidin	Neomycin Sulfate	Polymyxin B Sulfate
Production Method	Fermentation (Bacillus brevis)	Fermentation (Streptomyces fradiae)	Fermentation (Bacillus polymyxa)
API Complexity	Peptide mixture (linear & cyclic)	Aminoglycoside	Polypeptide
Primary Manufacturers	Sigma-Aldrich, Thermo Fisher, Bachem	Pfizer, Sanofi, Anhui Fengyuan, Divi's Labs	Xellia Pharmaceuticals, Qilu Pharmaceutical
Geographic Focus	North America, Europe (some Asia)	Asia (China, India), North America, Europe	Europe, China
Key Supply Risks	Raw material for fermentation, Purification	Agricultural input costs, Asian manufacturer competition, Environmental regs	Fermentation yield, Purification complexity, Regulatory scrutiny, Potential demand surge
Market Maturity	Mature, niche applications	Mature, broad applications	Mature, but increasing relevance due to AMR
Price Volatility	Moderate	Moderate to High	Moderate to High

Key Takeaways

The supply chain for Gramicidin, Neomycin Sulfate, and Polymyxin B Sulfate is characterized by specialized fermentation and purification processes. Manufacturing is concentrated in specific geographic regions, creating inherent risks from geopolitical events, regulatory changes, and logistical disruptions. Neomycin Sulfate production exhibits greater diversification, influenced by large-scale Asian manufacturers and agricultural input costs. Polymyxin B Sulfate faces challenges related to its complex purification and potential demand surges driven by the rise of antimicrobial resistance. Companies relying on these APIs must maintain robust supplier diversification strategies and closely monitor global regulatory and economic trends to mitigate supply chain risks.

FAQs

1. Are there any generic alternatives to these antibiotics that might impact their supply chain? The primary use of these antibiotics is in combination formulations, often as established generics themselves. The APIs are therefore crucial for the continued production of these established products. While new antibiotics are developed, the specific combination of Gramicidin, Neomycin Sulfate, and Polymyxin B Sulfate addresses particular spectrums of bacterial coverage for which direct generic API substitutes within the same combination are not typically sought; rather, the focus is on the reliable supply of these specific APIs for their existing applications.

2. What is the typical lead time for sourcing bulk quantities of these APIs? Lead times can vary significantly based on the manufacturer, order volume, and current market demand. Generally, for bulk pharmaceutical ingredients requiring fermentation, lead times can range from 3 to 9 months. This includes production cycles, quality control testing, and shipping. Advance planning and maintaining safety stock are essential.

3. How does the increasing global focus on environmental sustainability affect API manufacturing for these antibiotics? Stringent environmental regulations, particularly concerning wastewater discharge and emissions, necessitate significant capital investment by API manufacturers. This can increase production costs and, in some cases, lead to temporary or permanent closures of less compliant facilities. Companies must ensure their suppliers adhere to current environmental standards, which may involve audits and verification processes.

4. What are the primary quality control challenges associated with these fermentation-derived APIs? The primary challenges include ensuring batch-to-batch consistency in terms of potency, purity profile, and absence of critical impurities. For Gramicidin and Polymyxin B, the complex peptide nature requires advanced analytical techniques for characterization. Ensuring endotoxin levels are within acceptable limits is also critical, especially for ophthalmic or potential parenteral applications.

5. Are there any single points of failure in the supply chain for these specific APIs? While diversification of suppliers is a common strategy, reliance on specific geographic regions for a significant portion of global production can represent a vulnerability. For instance, if a major manufacturing hub in China or India experiences a widespread natural disaster, regulatory shutdown, or significant labor dispute, it could disproportionately impact the global supply of Neomycin Sulfate or Polymyxin B Sulfate. Similarly, specialized purification expertise for Gramicidin and Polymyxin B, if concentrated among a few firms, creates a potential bottleneck.

Citations

[1] Sigma-Aldrich. (n.d.). Gramicidin. Retrieved from https://www.sigmaaldrich.com/ (Note: Specific product pages vary and are generally accessed via login for bulk inquiries.)

[2] Thermo Fisher Scientific. (n.d.). Gramicidin. Retrieved from https://www.thermofisher.com/ (Note: Specific product pages vary and are generally accessed via login for bulk inquiries.)

[3] Bachem AG. (n.d.). Peptide Products. Retrieved from https://www.bachem.com/ (Note: Product offerings are customized, direct inquiry required for specific APIs.)

[4] Pfizer Inc. (n.d.). API Sourcing and Manufacturing. Retrieved from https://www.pfizer.com/ (Note: Bulk API information is typically handled through their B2B divisions, not public-facing product listings.)

[5] Sanofi S.A. (n.d.). API Manufacturing Capabilities. Retrieved from https://www.sanofi.com/ (Note: Information on specific API supply is often handled through their industrial affairs or B2B units.)

[6] CSL Limited. (n.d.). Products and Services. Retrieved from https://www.csl.com/ (Note: CSL's focus is often on biologics, but fermentation capabilities may extend to small molecules.)

[7] Anhui Fengyuan Pharmaceutical Co., Ltd. (n.d.). Product Portfolio. Retrieved from http://www.afpharma.com/ (Note: Company website provides general product categories, specific API availability requires direct contact.)

[8] Divi’s Laboratories Limited. (n.d.). Products. Retrieved from https://www.divislabs.com/ (Note: Company website lists broad API categories; specific antibiotic availability requires inquiry.)

[9] Xellia Pharmaceuticals ApS. (n.d.). APIs. Retrieved from https://www.xellia.com/ (Note: Xellia is a known major producer of Polymyxin B Sulfate, information available through their business development contacts.)

[10] Qilu Pharmaceutical Group. (n.d.). API Products. Retrieved from http://www.qilu-pharma.com/ (Note: Company website provides general product categories, specific API availability requires direct contact.)

[11] Gruppo Chiesi. (n.d.). API Manufacturing. Retrieved from https://www.chiesi.com/ (Note: While known for finished products, Chiesi has manufacturing capabilities for APIs. Specific sourcing requires inquiry.)

[12] Sandoz AG. (n.d.). Generic APIs. Retrieved from https://www.sandoz.com/ (Note: Sandoz, as a generics division of Novartis, has broad API sourcing and manufacturing capabilities.)